Cost-benefit of infection control interventions targeting methicillin-resistant Staphylococcus aureus in hospitals: Systematic review

Clinical Microbiology and Infection

Volumn 19, Issue 12, 2013, Pages

  Farbman, L ^a,b   Avni, T ^a,b   Rubinovitch, B ^a   Leibovici, L ^a,b   Paul, M ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Contact isolation; Cost benefit; Decolonization; Economic analysis; MRSA; Screening

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EMERGENCY CARE; ENDEMIC DISEASE; HEALTH CARE COST; HOSPITAL; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INTERVENTION STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT DURATION;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

CONTACT ISOLATION; COST-BENEFIT; DECOLONIZATION; ECONOMIC ANALYSIS; MRSA; SCREENING;

COST SAVINGS; COST-BENEFIT ANALYSIS; CROSS INFECTION; HOSPITALS; HUMANS; INFECTION CONTROL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 84888016820     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12280     Document Type: Article

References (57)

1. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166-174.
2. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004; 25: 425-430.
3. Gould IM, Reilly J, Bunyan D, Walker A. Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control. Clin Microbiol Infect 2010; 16: 1721-1728.
4. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 53-59.
5. Nulens E, Broex E, Ament A et al. Cost of the methicillin-resistant Staphylococcus aureus search and destroy policy in a Dutch University Hospital. J Hosp Infect 2008; 68: 301-307.
6. Kock R, Becker K, Cookson B et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010; 15: 19688.
7. Goetghebeur M, Landry PA, Han D, Vicente C. Methicillin-resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol 2007; 18: 27-34.
8. Health Protection Surveillance Centre. EARSS Surveillance Reports. Available at: http://www.ndsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/EARSSSurveillanceReports/
9. Johnson AP, Davies J, Guy R et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother 2012; 67: 802-809.
10. Ritchie K, Bradbury I, Craig J et al. The clinical and cost effectiveness of screening for meticillin-resistant Staphylococcus aureus (MRSA). 2007; 10; NHS Quality Improvement Scotland, HTA Report 9.
11. Bootsma MC, Diekmann O, Bonten MJ. Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. Proc Natl Acad Sci USA 2006; 103: 5620-5625.
12. Ofman JJ, Sullivan SD, Neumann PJ et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003; 9: 53-61.
13. Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect 2005; 11: 466-471.
14. Simoens S, Ophals E, Schuermans A. Search and destroy policy for methicillin-resistant Staphylococcus aureus: cost-benefit analysis. J Adv Nurs 2009; 65: 1853-1859.
15. van Rijen MM, Kluytmans JA. Costs and benefits of the MRSA Search and Destroy policy in a Dutch hospital. Eur J Clin Microbiol Infect Dis 2009; 28: 1245-1252.
16. Vriens M, Blok H, Fluit A, Troelstra A, Van Der Werken C, Verhoef J. Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10-year survey. Eur J Clin Microbiol Infect Dis 2002; 21: 782-786.
17. Rao N, Jacobs S, Joyce L. Cost-effective eradication of an outbreak of methicillin-resistant Staphylococcus aureus in a community teaching hospital. Infect Control Hosp Epidemiol 1988; 9: 255-260.
18. Nixon M, Jackson B, Varghese P, Jenkins D, Taylor G. Methicillin-resistant Staphylococcus aureus on orthopaedic wards: incidence, spread, mortality, cost and control. J Bone Joint Surg Br 2006; 88: 812-817.
19. West TE, Guerry C, Hiott M, Morrow N, Ward K, Salgado CD. Effect of targeted surveillance for control of methicillin-resistant Staphylococcus aureus in a community hospital system. Infect Control Hosp Epidemiol 2006; 27: 233-238.
20. Clancy M, Graepler A, Wilson M, Douglas I, Johnson J, Price CS. Active screening in high-risk units is an effective and cost-avoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospital. Infect Control Hosp Epidemiol 2006; 27: 1009-1017.
21. Knausz M, Kaproncai G, Rozgonyi F. Cost/benefit calculations of methicillin-resistant Staphylococcus aureus screening methods and their practical importance. Orv Hetil 2010; 151: 893-898.
22. Karchmer TB, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect 2002; 51: 126-132.
23. Gavalda L, Masuet C, Beltran J et al. Comparative cost of selective screening to prevent transmission of methicillin-resistant Staphylococcus aureus (MRSA), compared with the attributable costs of MRSA infection. Infect Control Hosp Epidemiol 2006; 27: 1264-1266.
24. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999; 282: 1745-1751.
25. Keshtgar MR, Khalili A, Coen PG et al. Impact of rapid molecular screening for methicillin-resistant Staphylococcus aureus in surgical wards. Br J Surg 2008; 95: 381-386.
26. Jernigan JA, Clemence MA, Stott GA et al. Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect Control Hosp Epidemiol 1995; 16: 686-696.
27. Leonhardt KK, Yakusheva O, Phelan D et al. Clinical effectiveness and cost benefit of universal versus targeted methicillin-resistant Staphylococcus aureus screening upon admission in hospitals. Infect Control Hosp Epidemiol 2011; 32: 797-803.
28. Nyman JA, Lees CH, Bockstedt LA et al. Cost of screening intensive care unit patients for methicillin-resistant Staphylococcus aureus in hospitals. Am J Infect Control 2011; 39: 27-34.
29. Bjorholt I, Haglind E. Cost-savings achieved by eradication of epidemic methicillin-resistant Staphylococcus aureus (EMRSA)-16 from a large teaching hospital. Eur J Clin Microbiol Infect Dis 2004; 23: 688-695.
30. Herr CE, Heckrodt TH, Hofmann FA, Schnettler R, Eikmann TF. Additional costs for preventing the spread of methicillin-resistant Staphylococcus aureus and a strategy for reducing these costs on a surgical ward. Infect Control Hosp Epidemiol 2003; 24: 673-678.
31. Papia G, Louie M, Tralla A, Johnson C, Collins V, Simor AE. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Infect Control Hosp Epidemiol 1999; 20: 473-477.
32. Tavolacci MP, Merle V, Dupuis M et al. Choice of a strategy for screening for methicillin-resistant Staphylococcus aureus on admission to rehabilitation units. Presse Med 2004; 33: 1575-1578.
33. Forward KR. The value of multiple surveillance cultures for methicillin-resistant Staphylococcus aureus. Am J Infect Control 2010; 38: 596-599.
34. Uckay I, Sax H, Iten A et al. Effect of screening for methicillin-resistant Staphylococcus aureus carriage by polymerase chain reaction on the duration of unnecessary preemptive contact isolation. Infect Control Hosp Epidemiol 2008; 29: 1077-1079.
35. Wassenberg MW, Kluytmans JA, Box AT et al. Rapid screening of methicillin-resistant Staphylococcus aureus using PCR and chromogenic agar: a prospective study to evaluate costs and effects. Clin Microbiol Infect 2010; 16: 1754-1761.
36. Conterno LO, Shymanski J, Ramotar K et al. Real-time polymerase chain reaction detection of methicillin-resistant Staphylococcus aureus: impact on nosocomial transmission and costs. Infect Control Hosp Epidemiol 2007; 28: 1134-1141.
37. Could IM, MacKenzie FM, MacLennan G, Pacitti D, Watson EJ, Noble DW. Topical antimicrobials in combination with admission screening and barrier precautions to control endemic methicillin-resistant Staphylococcus aureus in an Intensive Care Unit. Int J Antimicrob Agents 2007; 29: 536-543.
38. Walsh TJ, Vlahov D, Hansen SL et al. Prospective microbiologic surveillance in control of nosocomial methicillin-resistant Staphylococcus aureus. Infect Control 1987; 8: 7-14.
39. Morgan DJ, Day HR, Furuno JP et al. Improving efficiency in active surveillance for methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus at hospital admission. Infect Control Hosp Epidemiol 2010; 31: 1230-1235.
40. Spence MR, Dammel T, Courser S. Contact precautions for methicillin-resistant Staphylococcus aureus colonization: costly and unnecessary? Am J Infect Control 2012; 40: 535-538.
41. Garcia R, Vonderheid S, McFarlin B, Djonlich M, Jang C, Maghirang J. Cost and health outcomes associated with mandatory MRSA screening in a special care nursery. Adv Neonatal Care 2011; 11: 200-207.
42. Buhlmann M, Bogli-Stuber K, Droz S, Muhlemann K. Rapid screening for carriage of methicillin-resistant Staphylococcus aureus by PCR and associated costs. J Clin Microbiol 2008; 46: 2151-2154.
43. Creamer E, Galvin S, Dolan A et al. Evaluation of screening risk and nonrisk patients for methicillin-resistant Staphylococcus aureus on admission in an acute care hospital. Am J Infect Control 2012; 40: 411-415.
44. Bantar C, Sartori B, Vesco E et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003; 37: 180-186.
45. Frank MO, Batteiger BE, Sorensen SJ et al. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clin Perform Qual Health Care 1997; 5: 180-188.
46. Geissler A, Gerbeaux P, Granier I, Blanc P, Facon K, Durand-Gasselin J. Rational use of antibiotics in the intensive care unit: impact on microbial resistance and costs. Intensive Care Med 2003; 29: 49-54.
47. Souweine B, Traore O, Aublet-Cuvelier B et al. Role of infection control measures in limiting morbidity associated with multi-resistant organisms in critically ill patients. J Hosp Infect 2000; 45: 107-116.
48. Bishara J, Goldberg E, Leibovici L et al. Healthcare-associated vs. hospital-acquired Staphylococcus aureus bacteremia. Int J Infect Dis 2012; 16: e457-e463.
49. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50, 000 per quality-adjusted life-year decision rule? Med Care 2008; 46: 349-356.
50. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452.
51. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-342.
52. Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008; 46: 343-345.
53. Loveday HP, Pellowe CM, Jones SR, Pratt RJ. A systematic review of the evidence for interventions for the prevention and control of methicillin-resistant Staphylococcus aureus (1996-2004): report to the Joint MRSA Working Party (Subgroup A). J Hosp Infect 2006; 63 (suppl 1): S45-S70.
54. Tacconelli E, De Angelis G, de Waure C, Cataldo MA, La Torre G, Cauda R. Rapid screening tests for methicillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 546-554.
55. Cooper BS, Stone SP, Kibbler CC et al. Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): systematic review of the literature. BMJ 2004; 329: 533.
56. Korczak D, Schoffmann C. Medical and health economic evaluation of prevention- and control measures related to MRSA infections or -colonisations at hospitals. GMS Health Technol Assess 2010; 6: Doc04.
57. Stone SP, Cooper BS, Kibbler CC et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. J Antimicrob Chemother 2007; 59: 833-840.